Impact of Electronic Cigarette Temperature and Solvent on Biomarkers
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorMilton S. Hershey Medical Center
About this trial
This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.
Eligibility criteria
Qualifiers
21 years of age or older
Normal pulmonary and cardiovascular function with no history of COPD or cardiovascular disease (excluding hypertension)
Current exclusive use of a sub-ohm/mod or pod EC devices (≥ 1mL e-liquid/per day, ≥6 mg/ml nicotine concentration, EC for ≥ 1 year)
No plan on quitting nicotine use over the course of the study
Disqualifiers
Women who are pregnant and/or nursing or trying to become pregnant
Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)
Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV/AIDS, multiple sclerosis symptoms) or any medical disorder/medication that may affect participant safety or biomarker data
Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months
Trial design
Treatments tested in this trial
- High temperature wattage setting on electronic cigarette
- Low temperature wattage setting on electronic cigarette
- High concentration of Propylene Glycol
- Low concentration of Propylene Glycol
Treatment groups
50 Participants
are divided into 4 treatment groupsSponsors and collaborators
Milton S. Hershey Medical Center
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov